Development and validation of a nomogram for predicting taxane-based chemotherapy-induced peripheral neuropathy in patients with breast cancer: a two-center study

Abstract Taxane-based chemotherapy is a standard treatment for breast cancer but is frequently associated with moderate-to-severe chemotherapy-induced peripheral neuropathy (CIPN), which may necessitate dose reductions or treatment discontinuation. Given the limited efficacy of available interventions, early identification of patients at high risk of CIPN is essential. A total of 355 patients with breast cancer receiving taxane-based chemotherapy were enrolled in this two-center study, comprising a training cohort of 243 patients and an external validation cohort of 112 patients. Least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression were used to identify independent predictors and develop a nomogram. Model performance was evaluated in terms of discrimination, as measured by the area under the receiver operating characteristic curve (AUC), calibration, assessed using the Brier score, and clinical utility, evaluated by decision curve analysis (DCA). Five independent predictors were identified: history of diabetes, exercise habits, taxane type, body mass index, and age. The nomogram demonstrated good discriminatory performance, with AUCs of 0.835 (95% CI: 0.777–0.887) in the training cohort and 0.832 (95% CI: 0.741–0.911) in the external validation cohort. Calibration was satisfactory, with a Brier score of 0.146 and a calibration slope of 0.95, while DCA demonstrated the model's potential clinical utility. In conclusion, this nomogram provides an effective tool for predicting moderate-to-severe CIPN in patients with breast cancer receiving taxane-based chemotherapy, facilitating early risk stratification and informing personalized prevention and management strategies.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11348158/v1
Primary Topic
Cancer Treatment and Pharmacology
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Development and validation of a nomogram for predicting taxane-based chemotherapy-induced peripheral neuropathy in patients with breast cancer: a two-center study

Zhongyuan Yin, Mengzhe Zhang, Zhengle Zhang, Yiling Duan et al.
6 links
Research Square
Cancer Treatment and Pharmacology
preprint

Development and validation of a nomogram for predicting taxane-based chemotherapy-induced peripheral neuropathy in patients with breast cancer: a two-center study

Zhongyuan Yin, Mengzhe Zhang, Zhengle Zhang, Yiling Duan, Qiong Wang, Dan Li
preprint en

Abstract

Abstract Taxane-based chemotherapy is a standard treatment for breast cancer but is frequently associated with moderate-to-severe chemotherapy-induced peripheral neuropathy (CIPN), which may necessitate dose reductions or treatment discontinuation. Given the limited efficacy of available interventions, early identification of patients at high risk of CIPN is essential. A total of 355 patients with breast cancer receiving taxane-based chemotherapy were enrolled in this two-center study, comprising a training cohort of 243 patients and an external validation cohort of 112 patients. Least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression were used to identify independent predictors and develop a nomogram. Model performance was evaluated in terms of discrimination, as measured by the area under the receiver operating characteristic curve (AUC), calibration, assessed using the Brier score, and clinical utility, evaluated by decision curve analysis (DCA). Five independent predictors were identified: history of diabetes, exercise habits, taxane type, body mass index, and age. The nomogram demonstrated good discriminatory performance, with AUCs of 0.835 (95% CI: 0.777–0.887) in the training cohort and 0.832 (95% CI: 0.741–0.911) in the external validation cohort. Calibration was satisfactory, with a Brier score of 0.146 and a calibration slope of 0.95, while DCA demonstrated the model's potential clinical utility. In conclusion, this nomogram provides an effective tool for predicting moderate-to-severe CIPN in patients with breast cancer receiving taxane-based chemotherapy, facilitating early risk stratification and informing personalized prevention and management strategies.

Research Square
Wuhan University (CN), JiangSu Armed Police General Hospital (CN), Chinese People's Armed Police Force (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Cancer Treatment and Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon